Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers
Status:
Recruiting
Trial end date:
2026-09-26
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, prospective single-centered study. Subjects who meet the
inclusion/exclusion criteria will be allocated to appropriate cohorts: 1) gastric cancer, 2)
esophageal cancer and 3) hepatocellular carcinoma. Each cancer cohort group will be treated
with two cycles of neoadjuvant immune checkpoint inhibitor of IMC-001 (1 cycle = 2 weeks)
followed by curative resection and be followed up consecutively.